BridgeBio Pharma: Updated data keeps PROPEL3(ing) infigratinib in achondroplasia upwards

Research evidence excerpt

BridgeBio Pharma: Updated data keeps PROPEL3(ing) infigratinib in achondroplasia upwards

Accessible version

BridgeBio Pharma

Updated data keeps PROPEL3(ing)

infigratinib in achondroplasia upwards

Maintain Rating: BUY | PO: 101.00 USD | Price: 70.24 USD

Full dataset reinforces infigratinib’s differentiated profile 29 June 2026

Yesterday at ICCBH, BridgeBio presented the full phase 3 PROPEL3 data of infigratinib Equity

in achondroplasia (achon), alongside publication in NEJM. Overall, we think the update

Jason Zemansky

reinforces an already compelling topline (see note, Such great heights), with the oral Research Analyst

FGFR1-3 inhibitor driving statistically significant improvements in height velocity and BofAS +1 646 855 4280

height z-score alongside a good tolerable profile—supported by no treatment-related jason.zemansky@bofa.com

serious adverse events or discontinuations. Admittedly, expectations were high following Jacqueline Plesset

the initial disclosure; still, further support for long-term disease-modifying effects— ResearchBofAS Analyst

addressing the sequelae providers are more focused on—strengthens the case for a +1 646 855 0014

differentiated profile, in our view (see our note, 7 additional thoughts following jacqueline.plesset@bofa.com

BridgeBio’s achon data). Thus, while the update may not be stock-moving, we continue

to see infigratinib as likely practice-changing and a key contributor to BridgeBio’s

underappreciated longer-term growth outlook. Maintain Buy, $101 PO. Stock Data

Safety profile looks reassuring for chronic pediatric use Price 70.24 USD

Price Objective 101.00 USD

We wouldn’t be surprised if, heading into the full dataset, focus had centered on